Medical Doctor Program year 2025 Reported 2019–2025 Source: CMS Open Payments, 2026 publication

Alexander Veloso

Gastroenterology Coral Gables, FL Medical Doctor

NPI 1851629109 CMS profile 129845

5101 Sw 8Th Street, Suite 200, Coral Gables, FL 33134

Open in the dashboard

General payments

$13,718

692 records reported · program years 2019–2025

Research payments

$357

Paid to them · 1 record reported · program years 2019–2025

Ownership & investment interest

$0

None reported

Research they led as principal investigator

$349,620 paid to institutions, not to them · program years 2019–2025

Through program year 2025, Alexander Veloso of Coral Gables, FL is reported in the CMS Open Payments database as having received $13,718 across 692 general payments and $357 in research payments paid to them. Separately, studies naming them as principal investigator received $349,620 in research payments, paid to institutions rather than to them.

No combined total General, research and ownership are kept apart. Each is reported under its own rules, and ownership is not money that moved at all but the value of a stake held. A meal, a clinical trial grant and a shareholding do not add up to anything meaningful, so this site does not add them. The principal-investigator line is research money paid to institutions for studies they led — not to them — and is not added to anything either.

General payments for this record sit in the 86th percentile of Gastroenterology profiles with reported payments. Percentile describes the distribution, not the conduct.

By program year

8 rows
Year Kind Relative to this record's peak year Amount Records
2025 General $2,038 90
2024 General $1,490 69
2023 General $1,669 79
2023 Research $357 1
2022 General $2,071 100
2021 General $2,760 119
2020 General $1,520 94
2019 General $2,170 141

Beside peers

Year by year, beside peers General payments · among profiles paid that year
  • Alexander Veloso
  • Gastroenterology median
  • Middle half of Gastroenterology
  • National median

In program year 2025, general payments to Alexander Veloso were reported at $2,038. Among 13,050 Gastroenterology profiles paid that year, the median was $639 and the middle half received between $167 and $1,700.

Show as a table
Year Alexander Veloso Gastroenterology median Middle half National median
2019 $2,170 $417 $126–$1,100 $163
2020 $1,520 $224 $74–$624 $114
2021 $2,760 $352 $106–$1,054 $132
2022 $2,071 $448 $129–$1,270 $149
2023 $1,669 $533 $150–$1,390 $160
2024 $1,490 $605 $160–$1,606 $164
2025 $2,038 $639 $167–$1,700 $169

Breakdown

Who paid General payments · program years 2019–2025
  1. AbbVie, Inc. $3,174 170 payments
  2. Janssen Biotech, Inc. $2,108 107 payments
  3. Salix Pharmaceuticals, a division of Bausch Health US, LLC $1,404 115 payments
  4. Medtronic, Inc. $505 3 payments
  5. Janssen Scientific Affairs, LLC $490 6 payments
  6. Genzyme Corporation $489 22 payments
  7. Ardelyx, Inc. $399 25 payments
  8. FUJIFILM Medical Systems USA, Inc. $345 3 payments
  9. Ironwood Pharmaceuticals, Inc $340 23 payments
  10. Intercept Pharmaceuticals, Inc. $319 14 payments
  11. Other $4,145 204 payments

Every payment, record by record

What the payments were for General payments · program years 2019–2025
  1. Food and Beverage $13,505 688 payments
  2. Education $191 3 payments
  3. Consulting Fee $22 1 payment
Products named General payments · program years 2019–2025
  1. STELARA $1,854 84 payments
  2. XIFAXAN $1,083 89 payments
  3. TREMFYA $858 30 payments
  4. HUMIRA $753 41 payments
  5. SKYRIZI $752 39 payments
  6. CREON $740 40 payments
  7. LINZESS $632 55 payments
  8. RINVOQ $628 38 payments
  9. DUPIXENT $489 22 payments
  10. ZEPOSIA $435 12 payments
  11. Other $6,856 345 payments

A payment can name more than one product, so these amounts overlap and do not add up to the general-payment figure.

Research payments came from Research payments · program years 2019–2025
  1. Eli Lilly and Company $357 1 payment

Prescribing to Medicare patients

Part D · data year 2024 · 36 drugs

Part D claims

2,630

Median for Gastroenterology: 569

Drug cost

$1,438,603

Median for Gastroenterology: $104,976

Branded share of claims

44.3%

Median for Gastroenterology: 31.8%

Drugs this doctor was counted under in Medicare Part D 2024, by drug cost
Drug Type Relative to their largest Claims Drug cost
Stelara Ustekinumab Brand 22 $599,207
Humira Pen Adalimumab Brand 16 $204,354
Creon Lipase/Protease/Amylase Brand 46 $166,124
Zenpep Lipase/Protease/Amylase Brand 22 $110,430
Linzess Linaclotide Brand 134 $89,033
Remicade Infliximab Brand 13 $60,466
Ibsrela Tenapanor Hcl Brand 24 $44,336
Xifaxan Rifaximin Brand 16 $35,044
Sod Sulf-Potass Sulf-Mag Sulf Sodium, Potassium,mag Sulfates Brand 293 $18,271
Clenpiq Sod Picosulf/Mag Ox/Citric Ac Brand 96 $16,339

The 10 drugs with the highest cost, of 36 counted.

Drug cost is what was paid for the drugs at the pharmacy — by Medicare, the patient and others — and is not money to the prescriber. Medicare Part D only: drugs dispensed to Medicare beneficiaries. A drug with fewer than 11 claims for this prescriber is not published, so a missing drug does not mean zero. The medians are for the 14,294 Part D prescribers listed as Gastroenterology; they describe a distribution and say nothing about conduct.

Billing to Medicare

Part B · data year 2024 · 30 billing codes

Paid by Medicare

$36,541

Medicare's payments for the services billed

Medicare patients

174

Average age 73

Services billed

1,175

97 women, 77 men among their patients

Share of this provider's Medicare patients with each condition
Condition among their Medicare patients Relative to the most common Share of patients
High blood pressure 75%
Arthritis 54%
Depression 49%
Diabetes 44%
Ischemic heart disease 39%
Chronic kidney disease 38%
COPD 31%
Heart failure 24%

Medicare Part B only: services billed to Medicare. Rows covering fewer than 11 beneficiaries are not published. Only drugs given in the clinic are itemised here; the rest of what this provider billed is in the total above.

Payments and prescribing

First 5 of 18 products · payments 2024

Two separate records. The payments come from Open Payments and the claims from Medicare. They are set side by side because they name the same product; they do not show that a payment affected a prescription.

Products this doctor was paid in connection with in 2024, beside Medicare claims for the same product
Product Paid by Related payments Part D claims Part B services
DUPIXENT
  • GENZYME CORPORATION $125
  • Regeneron Healthcare Solutions, Inc. $65
$191 — —
STELARA
  • Janssen Biotech, Inc. $152
$152 22 —
VOQUEZNA
  • Phathom Pharmaceuticals, Inc. $147
$147 — —
IBSRELA
  • Ardelyx, Inc. $132
$132 24 —
TREMFYA
  • Janssen Biotech, Inc. $109
$109 — —

A dash means Medicare published no figure for this doctor and product — fewer than 11 claims, or the product is not covered under that part — which is not the same as none. Payments are general payments only; one that names several products is split evenly between them, so an amount is payments related to the product, not money paid for it.

See all 18 in the dashboard with a free account

Records

693 reported

Every payment, record by record

Date, company, amount, what it was for and the product named — filter by year, kind and company, or download as CSV.

Other Gastroenterology in Florida

Related records

What this means

U.S. law requires drug and medical device manufacturers to report payments and transfers of value they make to physicians and teaching hospitals. The Centers for Medicare & Medicaid Services publishes that record each year. This page shows what was reported about this person, and nothing else.

An ownership interest is different from the other two. It is not a payment: it is a stake — shares, options, a partnership holding — that a physician or an immediate family member held in a manufacturer during that year. The figure shown is what the stake was reported to be worth.

Research payments frequently pass through a clinician to the institution running a trial, and rarely represent personal income. They should be read differently from general payments.

Provenance

Source: CMS Open Payments · through program year 2025

Data current to program year 2025, from CMS's 2026 publication.

We reproduce what manufacturers reported. We do not verify, edit or correct the underlying records.

A payment record is not evidence of wrongdoing. Financial relationships between industry and medicine are legal, common and often necessary for research. Who Paid My Doc reports what was disclosed; it does not judge it.

Who Paid My Doc is independent and is not affiliated with, endorsed by or sponsored by CMS or any U.S. government agency. It is not a consumer reporting agency and this is not a consumer report; do not use it for decisions covered by the Fair Credit Reporting Act.

How to dispute or correct a record